Vaccinomics and Personalized Vaccinology: Is Science Leading Us Toward a New Path of Directed Vaccine Development and Discovery?

English version České info

As is apparent in many fields of science and medicine, the new biology, and particularly new high-throughput genetic sequencing and transcriptomic and epigenetic technologies, are radically altering our understanding and views of science. In this article, we make the case that while mostly ignored thus far in the vaccine field, these changes will revolutionize vaccinology from development to manufacture to administration. Such advances will address a current major barrier in vaccinology—that of empiric vaccine discovery and development, and the subsequent low yield of viable vaccine candidates, particularly for hyper-variable viruses. While our laboratory's data and thinking (and hence also for this paper) has been directed toward viruses and viral vaccines, generalization to other pathogens and disease entities (i.e., anti-cancer vaccines) may be appropriate.

Vyšlo v časopise: Vaccinomics and Personalized Vaccinology: Is Science Leading Us Toward a New Path of Directed Vaccine Development and Discovery?. PLoS Pathog 7(12): e32767. doi:10.1371/journal.ppat.1002344
Kategorie: Opinion
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1002344

Souhrn

Zdroje

1. BrusicVAugustJT 2004 The changing field of vaccine development in the genomics era. Pharmacogenomics 5 597 600

2. PolandGAOvsyannikovaIGJacobsonRMSmithDI 2007 Heterogeneity in vaccine immune response: The role of immunogenetics and the emerging field of vaccinomics. Clinical Pharmacology and Therapeutics 82 653 664

3. PolandGAOvsyannikovaIGJacobsonRM 2008 Personalized vaccines: The emerging field of vaccinomics. Expert Opinion on Biological Therapy 8 1659 1667

4. PolandGA 2007 Pharmacology, vaccinomics, and the 2nd golden age of vaccinology. Clinical Pharmacology and Therapeutics 82 623 626

5. SetteARappuoliR 2010 Reverse vaccinology: developing vaccines in the era of genomics. Immunity 33 530 541

6. HeYRappuoliRDe GrootASChenRT 2010 Emerging vaccine informatics. J Biomed Biotechnol 2010 218590

7. FalugiFPetraccaRMarianiMLuzziEManciantiS 2001 Rationally designed strings of promiscuous CD4(+) T cell epitopes provide help to Haemophilus influenzae type b oligosaccharide: a model for new conjugate vaccines. Eur J Immunol 31 3816 3824

8. AssarssonEGreenbaumJASundstromMSchafferLHammondJA 2008 Kinetic analysis of a complete poxvirus transcriptome reveals an immediate-early class of genes. Proc Natl Acad Sci U S A 105 2140 2145

9. MoutaftsiMTscharkeDCVaughanKKoelleDMSternL 2010 Uncovering the interplay between CD8, CD4 and antibody responses to complex pathogens. Future Microbiol 5 221 239

10. GreenMSShohatTLermanYCohenDSleponR 1994 Sex differences in the humoral antibody response to live measles vaccine in young adults. International Journal of Epidemiology 23 1078 1081

11. NairNGansHLew-YasukawaLLong-WagarACArvinA 2007 Age-dependent differences in IgG isotype and avidity induced by measles vaccine received during the first year of life. J Infect Dis 196 1339 1345

12. HsuLCLinSRHsuHMChaoWHHsiehJT 1996 Ethnic differences in immune responses to hepatitis B vaccine. American Journal of Epidemiology 143 718 724

13. CouchRBWinokurPBradyRBelsheRChenWH 2007 Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine 25 7656 7663

14. HaworthEABooyRStirzakerLWilkesSBattersbyA 1993 Is the cold chain for vaccines maintained in general practice? British Medical Journal 307 242 244

15. GaucherDTherrienRKettafNAngermannBRBoucherG 2008 Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med 205 3119 3131

16. MiddlemanABAndingRTungC 2010 Effect of needle length when immunizing obese adolescents with hepatitis B vaccine. Pediatrics 125 e508 e512

17. WinterAPFollettEAMcIntyreJStewartJSymingtonIS 1994 Influence of smoking on immunological responses to hepatitis B vaccine. Vaccine 12 771 772

18. SpielbergSP 1998 Therapeutics and toxicology. Current Opinion in Pediatrics 10 201 202

19. PolandGAOvsyannikovaIGJacobsonRMSmithDI 2007 Heterogeneity in vaccine immune response: the role of immunogenetics and the emerging field of vaccinomics. Clin Pharmacol Ther 82 653 664

20. PolandGAOvsyannikovaIGJacobsonRM 2009 Application of pharmacogenomics to vaccines. Pharmacogenomics 10 837 852

21. JerneNK 1974 Towards a network theory of the immune system. Ann Immunol (Paris) 125C 373 389

22. PolandGAOvsyannikovaIGJacobsonRM 2008 Vaccine immunogenetics: bedside to bench to population. Vaccine 26 6183 6188

23. HaralambievaIHPolandGA 2010 Vaccinomics, predictive vaccinology and the future of vaccine development. Future Microbiol 5 1757 1760 10.2217/fmb.10.146 [doi]

24. JacobsonRMOvsyannikovaIGTargonskiPVPolandGA 2007 Studies of twins in vaccinology. Vaccine 25 3160 3164

25. TanPLJacobsonRMPolandGAJacobsenSJPankratzSV 2001 Twin studies of immunogenicity -⁠ determining the genetic contribution to vaccine failure. Vaccine 19 2434 2439

26. PolandGAJacobsonRMVierkantRAColbourneSAThampyAM 2002 Effect of differing immunization policies on circulating measles antibody levels in US and Canadian children. Mayo Clin Proc 77 446 451

27. PolandGAJacobsonRMColbourneSAThampyAMLipskyJJ 1999 Measles antibody seroprevalence rates among immunized Inuit, Innu and Caucasian subjects. Vaccine 17 1525 1531

28. PolandGAJacobsonRMThampyAMColbourneSAWollanPC 1997 Measles re-immunization in children seronegative after initial immunization. Journal of the American Medical Association 277 1156 1158

29. St.SauverJLDhimanNOvsyannikovaIGJacobsonRMVierkantRA 2005 Extinction of the human leukocyte antigen homozygosity effect after two doses of the measles-mumps-rubella vaccine. Human Immunology 66 788 798

30. OvsyannikovaIGDhimanNJacobsonRMVierkantRAPankratzVS 2007 HLA homozygosity does not adversely effect measles vaccine-induced cytokine responses. Virology 364 87 94

31. OvsyannikovaIGPankratzVSVierkantRAJacobsonRMPolandGA 2006 Human leukocyte antigen haplotypes in the genetic control of immune response to measles-mumps-rubella vaccine. J Infect Dis 193 655 663

32. OvsyannikovaIGJacobsonRMVierkantRAPankratzVSPolandGA 2007 HLA supertypes and immune responses to measles-mumps-rubella viral vaccine: Findings and implications for vaccine design. Vaccine 25 3090 3100

33. DhimanNCunninghamJMJacobsonRMVierkantRAWuY 2007 Variations in measles vaccine-specific humoral immunity by polymorphisms in SLAM and CD46 measles virus receptors. Journal of Allergy and Clinical Immunology 120 666 672

34. OvsyannikovaIGHaralambievaIHVierkantRAPankratzVSPolandGA 2011 The role of polymorphisms in Toll-like receptors and their associated intracellular signaling genes in measles vaccine immunity. Hum Genet 130 547 561

35. DhimanNOvsyannikovaIGCunninghamJMVierkantRAKennedyRB 2007 Associations between measles vaccine immunity and single nucleotide polymorphisms in cytokine and cytokine receptor genes. J Infect Dis 195 21 29

36. HaralambievaIHOvsyannikovaIGUmlaufBJVierkantRAPankratzSV 2011 Genetic polymorphisms in host antiviral genes: associations with humoral and cellular immunity to measles vaccine. Vaccine 29 8988 8997

37. OvsyannikovaIGHaralambievaIHVierkantRAO'ByrneMMJacobsonRM 2011 The association of CD46, SLAM, and CD209 cellular receptor gene SNPs with variations in measles vaccine-induced immune responses--a replication study and examination of novel polymorphisms. Hum Hered 72 306 323

38. HaralambievaIHOvsyannikovaIGKennedyRBVierkantRAPankratzSV 2011 Associations between single nucleotide polymorphisms and haplotypes in cytokine and cytokine receptor genes and immunity to measles vaccination. Vaccine 29 7883 7895

39. WangCTangJSongWLobashevskyEWilsonCM 2004 HLA and cytokine gene polymorphisms are independently associated with responses to hepatitis B vaccination. Hepatology 39 978 988

40. KimMJNafzigerANHarroCDKeyserlingHLRamseyKM 2003 Revaccination of healthy nonresponders with hepatitis B vaccine and prediction of seroprotection response. Vaccine 21 1174 1179

41. LeeHGLimJSLeeKYChoiYKChoeIS 1997 Peptide-specific CTL induction in HBV-seropositive PBMC by stimulation with peptides in vitro: novel epitopes identified from chronic carriers. Virus Research 50 185 194

42. DeanMCarringtonMO'BrienSJ 2002 Balanced polymorphism selected by genetic versus infectious human disease. Annu Rev Genomics Hum Genet 3 263 292

43. FitzgeraldKAGolenbockDT 2007 Immunology. The shape of things to come. Science 316 1574 1576

44. OvsyannikovaIGJohnsonKLMuddimanDCVierkantRAPolandGA 2004 Identification and characterization of novel, naturally processed measles virus class II HLA-DRB1 peptides. Journal of Virology 78 42 51

45. JohnsonKLOvsyannikovaIGPolandGMuddimanDC 2005 Identification of class II HLA-DRB1*03-bound measles virus peptides by 2D-liquid chromatography tandem mass spectrometry. Journal of Proteome Research 4 2243 2249

46. JohnsonKLOvsyannikovaIGMaddenBJPolandGAMuddimanDC 2005 Accurate mass precursor ion data and tandem mass spectrometry identify a class I Human Leukocyte Antigen A*0201-presented peptide originating from vaccinia virus. Journal of American Society for Mass Spectrometry 16 1812 1817

47. JohnsonKLOvsyannikovaIGMasonCJBergen HRIIIPolandGA 2009 Discovery of naturally processed and HLA-presented class I peptides from vaccinia virus infection using mass spectrometry for vaccine development. Vaccine 28 38 47

48. OvsyannikovaIGJohnsonKLBergenHRIIIPolandGA 2007 Mass spectrometry and peptide-based vaccine development. Clinical Pharmacology and Therapeutics 82 644 652

49. QuerecTDAkondyRSLeeEKCaoWNakayaHI 2009 Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 10 116 125

50. NakayaHIWrammertJLeeEKRacioppiLMarie-KunzeS 2011 Systems biology of vaccination for seasonal influenza in humans. Nat Immunol 12 786 795